What Soon-Shiong has delivered, Encanta's RSV antiviral, and other biotech news from The Readout research advocacy chronic disease Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Newsletter The Readout Cambrian’s experimental longevity drug mimics exercise What Soon-Shiong has delivered, Encanta’s RSV antiviral, and other biotech news from…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Washington’s vaccine wars are escalating again as Senate Democrats seek to build a paper trail around Health Secretary Robert F. Kennedy Jr.’s controversial overhaul of the CDC’s vaccine advisory committee.
Also, Enanta’s pushing forward with its RSV antiviral, we take a critical look at Patrick Soon-Shiong’s pancreatic cancer claims, and some news from longevity player Cambria.
Continue to STAT+ to read the full story…
US Pharma Marketing